HBPCD
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with … Read more
Market Cap & Net Worth: HBPCD (HBPCD)
HBPCD (PINK:HBPCD) has a market capitalization of $4.26K ($4.26K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #46240 globally and #14432 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HBPCD's stock price $0.45 by its total outstanding shares 9372 (9.37K).
HBPCD Market Cap History: 2015 to 2024
HBPCD's market capitalization history from 2015 to 2024. Data shows growth from $72.13K to $4.26K (0.00% CAGR).
HBPCD Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HBPCD's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HBPCD by Market Capitalization
Companies near HBPCD in the global market cap rankings as of March 19, 2026.
Key companies related to HBPCD by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
HBPCD Historical Marketcap From 2015 to 2024
Between 2015 and today, HBPCD's market cap moved from $72.13K to $ 4.26K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | $4.26K | -37.26% |
| 2023 | $6.79K | -9.38% |
| 2022 | $7.50K | -36.00% |
| 2021 | $11.71K | -40.45% |
| 2020 | $19.67K | -58.46% |
| 2019 | $47.35K | +169.47% |
| 2018 | $17.57K | -33.39% |
| 2017 | $26.38K | -43.30% |
| 2016 | $46.53K | -35.49% |
| 2015 | $72.13K | -- |
End of Day Market Cap According to Different Sources
On Nov 26th, 2025 the market cap of HBPCD was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.26K USD |
| MoneyControl | $4.26K USD |
| MarketWatch | $4.26K USD |
| marketcap.company | $4.26K USD |
| Reuters | $4.26K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.